Novartis Signs US$1.7 B Deal with Bicycle Therapeutics for Cancer Radiopharmaceuticals.

Adding to its existing radiopharmaceutical portfolio, Novartis has signed a collaboration with Bicycle Therapeutics to develop, manufacture and commercialise Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. The deal, which is worth up to US$1.7 B, will leverage Bicycle's bicyclic peptide (Bicycle®) technology to develop medicines with favourable drug-like properties. The collaboration comes shortly after Novartis announced it was implementing a new strategy of focusing on only a limited number of therapeutic areas and was therefore cutting several of its existing partnerships. [ABSTRACT FROM AUTHOR]

Copyright of PharmaDeals Review is the property of IMS Health and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)